The sex hormone system in carriers of BRCA1/2 mutations: A case-control study

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages 1226-1232

  Widschwendter, Martin ^a   Rosenthal, Adam N ^a,b   Philpott, Sue ^a   Rizzuto, Ivana ^a   Fraser, Lindsay ^a   Hayward, Jane ^a   Intermaggio, Maria P ^c   Edlund, Christopher K ^c   Ramus, Susan J ^c   Gayther, Simon A ^c   Dubeau, Louis ^d   Fourkala, Evangelia Ourania ^a   Zaikin, Alexey ^a   Menon, Usha ^a   Jacobs, Ian J ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL; PROGESTERONE;

AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIAL THICKNESS; FEMALE; FOLLICULAR PHASE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HORMONE SYNTHESIS; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; SEX HORMONE DETERMINATION;

AREA UNDER CURVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; ESTRADIOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HETEROZYGOTE; HUMANS; LOGISTIC MODELS; MENSTRUAL CYCLE; MUTATION; ODDS RATIO; OVARIAN NEOPLASMS; PENETRANCE; PHENOTYPE; PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886718942     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70448-0     Document Type: Article

References (26)

1. King MC, Marks JH, Mandell JB Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.
2. Venkitaraman AR Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
3. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
4. Dubeau L The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008, 9:1191-1197.
5. Chodankar R, Kwang S, Sangiorgi F, et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005, 15:561-565.
6. Hong H, Yen HY, Brockmeyer A, et al. Changes in the mouse estrus cycle in response to Brca1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 2010, 70:221-228.
7. Yen HY, Gabet Y, Liu Y, et al. Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab Invest 2012, 92:802-811.
8. Zhou J, Dsupin BA, Giudice LC, Bondy CA Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1994, 79:1723-1734.
9. Werner H, Bruchim I IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 2012, 13:e537-e544.
10. Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013, 31:49-57.
11. Brisken C Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 2013, 13:385-396.
12. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013, 14:1009-1019. Endogenous Hormones and Breast Cancer Collaborative Group.
13. Beral V Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
14. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
16. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
17. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006, 314:1467-1470.
18. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012, 366:421-432.
19. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012, 366:409-420.
20. Segev Y, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013, 130:127-131.
21. Beral V, Bull D, Green J, Reeves G Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007, 369:1703-1710.
22. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335:1134.
23. Li Q, Kannan A, DeMayo FJ, et al. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 2011, 331:912-916.
24. Yang S, Thiel KW, Leslie KK Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011, 22:145-152.
25. Suzuki T, Miki Y, Ohuchi N, Sasano H Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 2008, 15:270-277.
26. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013, 5:172ra21.